Artwork

Content provided by Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Optimal Treatment of Metastatic TNBC

29:30
 
Share
 

Manage episode 313769701 series 3286120
Content provided by Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Presenter:

Hope S. Rugo MD
Professor of Medicine
University of California
San Francisco Comprehensive Cancer Center

TNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subtype is very aggressive, with a median overall survival slightly greater than 1 year. Furthermore, treatment options are limited. New and innovative therapies are being evaluated in patients to improve their outcomes, including progression-free survival and time to deterioration in health-related quality of life. Here, we present an expert-led review on current standards of care, as well as novel and emerging treatment regimens that are in the pipeline for approval by the United States Food and Drug Administration and/or under investigation.

Follow along with the slideset located here:
https://bit.ly/3krD3Gj

  continue reading

4 episodes

Artwork
iconShare
 
Manage episode 313769701 series 3286120
Content provided by Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Presenter:

Hope S. Rugo MD
Professor of Medicine
University of California
San Francisco Comprehensive Cancer Center

TNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subtype is very aggressive, with a median overall survival slightly greater than 1 year. Furthermore, treatment options are limited. New and innovative therapies are being evaluated in patients to improve their outcomes, including progression-free survival and time to deterioration in health-related quality of life. Here, we present an expert-led review on current standards of care, as well as novel and emerging treatment regimens that are in the pipeline for approval by the United States Food and Drug Administration and/or under investigation.

Follow along with the slideset located here:
https://bit.ly/3krD3Gj

  continue reading

4 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide